Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on May 23, 2014. The report discloses a corporate event regarding the upcoming presentation of clinical trial data for the company's lead candidate, NSI-189, in the treatment of major depressive disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event and does not contain financial statements or performance metrics.
Material Changes
There are no material financial changes reported in this filing. The significant event is the announcement that data from the NSI-189 Phase Ib study will be presented at the American Society of Clinical Psychopharmacology Annual Meeting on June 17, 2014, in Hollywood, Florida.
Outlook, Risks, and Management Commentary
Management commentary is limited to the disclosure of the upcoming data presentation. The filing references a press release (Exhibit 99.01) for further details but does not include specific guidance, risk factors, or contingencies within the body of this 8-K text.
Investor Verification Checklist
- Verify the content of the press release attached as Exhibit 99.01 for specific details on the NSI-189 Phase Ib study results.
- Confirm the date and location of the American Society of Clinical Psychopharmacology Annual Meeting (June 17, 2014, Hollywood, Florida).
- Note that the registrant name in the filing is Neuralstem, Inc., despite the request metadata referencing Palisade Bio, Inc.